CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 20 enrolled
Drug / intervention
Placebo +1 moreother
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT06755489
NCT06755489N/ACompleted
CompareCT.gov

Evaluation of Quality of Life in a Cohort of Diarrhoeic Irritable Bowel Syndrome (IBS-D) Patients Assuming GABA.

University of Pisa·interventional·Posted Jan 1, 2025·Updated Feb 5, 2026

In Brief

A clinical study evaluating Placebo and GABA for Diarrhoea Predominant Irritable Bowel Syndrome. Completed, enrolled 20 participants across 2 sites.

Detailed Summary

The study aims to evaluate the impact on quality of life and abdominal discomfort of GABA and Melissa food supplement administration in patients with diarrhea-predominant irritable bowel syndrome.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsDiarrhoea Predominant Irritable Bowel Syndrome
CountriesItaly
CollaboratorsAzienda Ospedaliero, Universitaria Pisana

Timeline

N/ACompletedFinished
202420252026
First PostedJan 1, 2025
Enrollment StartApr 17, 2023
Primary CompletionNov 19, 2024
Study CompletionMar 21, 2025
TodayJul 2, 2026
Enrollment to primary: 1.6 yearsPosted 1.5 years ago

Interventions

Placeboother

530 mg tablets containing microcrystalline cellulose, rice bran, bitter cocoa powder table 530 mg. 1 tablet three times a day

GABAother

530 mg tablets containing Gamma-aminobutyric acid (GABA) and different bulking agent as microcrystalline cellulose, calcium carbonate, lemon balm d.e. Leaves (melissa officinalis l. - maltodextrin) tit. 2% in rosmarinic acid, anti-caking agents: silicon dioxide, vegetable magnesium stearate. 1 tablet three times a day